La Montagna G, Parenti M, Oliani C, Filippi F, Tirri G
I Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli.
Riv Eur Sci Med Farmacol. 1990 Aug-Oct;12(4-5):265-72.
The anti-inflammatory and analgesic activity of the beta-cyclodextrin-piroxicam (beta CDP) complex was assessed in a randomized single-blind controlled parallel study vs nabumetone (NAB). Forty patients, 18 men and 22 women aged 18 to 65 and suffering from chronic osteoarthritis, were treated. Both drugs were orally administered, once a day in the morning, for 4 consecutive weeks. PI and SPID, evaluated for 24 hours following the first drug administration, showed a quicker onset of the analgesic action of beta CDP, with statistically significant differences between treatments (p less than 0.05). In the medium-term treatment, beta CDP proved to be more effective on joint swelling, spontaneous pain, pain on passive movement and functional limitation. Both treatments were well tolerated but a higher gastro-intestinal side-effect incidence was recorded in NAB group.
在一项随机单盲对照平行研究中，对β-环糊精-吡罗昔康（βCDP）复合物与萘丁美酮（NAB）的抗炎和镇痛活性进行了评估。40名年龄在18至65岁之间、患有慢性骨关节炎的患者（18名男性和22名女性）接受了治疗。两种药物均口服给药，每天早上一次，连续服用4周。在首次给药后24小时进行评估的疼痛强度（PI）和疼痛强度差异总和（SPID）显示，βCDP的镇痛作用起效更快，治疗之间存在统计学显著差异（p<0.05）。在中期治疗中，βCDP被证明对关节肿胀、自发疼痛、被动运动时的疼痛和功能受限更有效。两种治疗的耐受性都很好，但NAB组记录到更高的胃肠道副作用发生率。
